Stockreport

Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder

Supernus Pharmaceuticals, Inc.  (SUPN) 
Last supernus pharmaceuticals, inc. earnings: 2/25 04:40 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.supernus.com
PDF Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is a novel, first-in-class [Read more]